Yes, in the United States Rybelsus is on its way out, and the Ozempic pill is taking its place. Novo Nordisk's patient page says it plainly: Rybelsus is being replaced by the Ozempic pill, and your prescriber will guide you through the change.1 This is a business decision by the maker, a rename plus a new tablet. It is not a recall, and nothing in the sources we read points to a safety problem.
What is actually happening
Three things are true at once, and most of the confusion comes from people hearing only one of them.
- Novo is stopping supply. Novo told Illinois Medicaid it will discontinue every strength of Rybelsus. Shipments to wholesalers were to stop in May 2026, with pharmacy stock expected to run short from July 2026.2
- The drug is not going anywhere. The Ozempic pill is the same active ingredient, semaglutide, with the same prescribing information. Only the tablet strengths are different.3
- FDA has not delisted it. On FDA's own approvals database, all three Rybelsus strengths (3, 7 and 14 mg) still show a marketing status of Prescription, on the same application as the three Ozempic tablet strengths.7 So if a pharmacy still has Rybelsus on the shelf, it can fill it.
Put simply: if your refill is getting harder to find, that is the supply winding down, not your pharmacy making a mistake.
Why the numbers on the bottle changed
The new tablet absorbs better, so it needs fewer milligrams to put the same amount of semaglutide in your blood. The FDA label puts absorption at about 0.4% to 1% for Rybelsus and 1% to 2% for the Ozempic tablets.5 In a study in healthy volunteers, the paired strengths produced no clinically significant difference in blood levels.5 That is why a lower number on the new bottle is not a lower dose of medicine.
| Rybelsus | Ozempic pill | What the label says about switching |
|---|---|---|
| 3 mg (first 30 days) | 1.5 mg (first 30 days) | Do not switch during the first 30 days4 |
| 7 mg | 4 mg | Paired in the label's switch table4 |
| 14 mg | 9 mg | Paired in the label's switch table4 |
The label's rules for the move, in its own words: do not switch between the two during the initiation phase (days 1 to 30); after 30 days patients may switch; and the new tablet starts the day after the last dose of the old one.4 New patients now start on the Ozempic pill's own first-month strength, which the label notes is not meant to control blood sugar on its own.6 Which strength you move to is your prescriber's decision, not ours and not the pharmacy's.
Do not cut, combine or swap tablets yourself to match the old milligram number. A 7 mg Rybelsus and a 4 mg Ozempic pill are matched by the label; a 7 mg dose of the new tablet would not be. Ask for the new prescription instead.
What you need to do
- Ask for a new prescription. Novo says anyone taking Rybelsus needs one to move to the Ozempic pill, and to talk to their prescriber about the right strength.1 A pharmacist cannot convert it for you.
- Check whether your plan wants new paperwork. Illinois Medicaid, for one, does not convert patients automatically and requires a new prior authorization for the Ozempic tablets.3 Commercial and Medicare plans set their own rules, so call the number on your card before your last Rybelsus bottle runs out.
- Keep your savings offer. If you signed up for a Rybelsus savings offer, Novo says you can keep using it on Ozempic without enrolling again.9 The details are in the Rybelsus coupon guide.
- Do not stockpile on a whim. Your plan still decides how many days you can fill at once, and supply is shrinking anyway.
Will it cost more?
With insurance, it should not. Novo says the Ozempic pill will have the same coverage as Rybelsus, and that your cost depends on your plan.1 The commercial savings offer works the same way it did before: pay as little as $25, with the saving capped at $100 a month, and anyone on Medicare, Medicaid or another government plan excluded.8
Without coverage, the Ozempic pill has a published cash price. Novo lists self-pay options for the Ozempic pill starting at $149 a month for people whose commercial plan does not cover it or who have no insurance, with the price varying by dose.8 Novo also says government-insured patients may use that self-pay program if they pay themselves outside their insurance.8 For Medicare, trying Part D coverage for a diabetes prescription first usually makes more sense.
If you are paying cash and are open to a compounded tablet rather than the brand, the programs we track that sell oral semaglutide are below, ranked by today's price. The cheapest starts at $147 a month. Compounded drugs are not FDA-approved products, and they are not the Ozempic pill; here is what that means.
Is it the same as the Wegovy pill?
No, and the names make this easy to mix up. The Ozempic pill is the Rybelsus replacement, labelled for type 2 diabetes.3 The Wegovy pill is a separate oral semaglutide product for weight management, with its own strengths and its own label. If you were taking Rybelsus off-label for weight, that conversation belongs with your prescriber; our guide to every GLP-1 pill lays the products side by side, and Rybelsus for type 2 diabetes covers the drug itself.
The bottom line
Rybelsus is being discontinued in the US by its maker, not by FDA, and not for safety. The same medicine continues as the Ozempic pill at 4 mg and 9 mg in place of 7 mg and 14 mg.4 Get the new prescription before your stock runs out, keep your savings offer, and if you pay cash, compare Novo's price with the board above.
